Full Breakdown
Eli Lilly’s Foundayo Faces Slower Uptake Than Novo Nordisk’s Wegovy in Early Weeks
4/25/2026, 9:44:42 AM
Launch and Early Prescription Numbers for Foundayo
Eli Lilly & Co. received FDA approval for its oral weight-loss pill Foundayo on April 1, 2026. Prescriptions began through LillyDirect on April 6 and the drug entered retail pharmacies and telehealth on April 9. In its debut week the medication recorded 1,390 prescriptions; the second week rose to 3,707, per IQVIA data.
Background: Obesity-Drug Landscape and Prior Approvals
Novo Nordisk A/S entered the oral obesity-pill market in January 2026 with an oral version of its semaglutide-based Wegovy. Wegovy logged 3,071 prescriptions in its first full week and jumped to 18,410 in the second week, establishing a clear first-mover edge. Its injectable semaglutide products, Wegovy and Ozempic, have driven a turnaround for the Danish firm.
Prescription Volume and Market Share
Foundayo’s second-week prescription count of 3,707 trails Wegovy’s 18,410. Lilly’s shares fell 1.5 % before the market opened and 2.6 % by 9:35 a.m. ET, while Novo’s shares rose 2 % pre-open and 4 % later in Denmark. Analysts say about 300,000 prescriptions by year-end are needed to reach projected 2026 sales of $1.3-$1.5 billion, down from earlier $5 billion expectations.
Official Statements & Responses
Lilly warned that early weekly figures are “not fully comprehensive” and may miss prescriptions from some pharmacy partners, urging investors to view the data over time. RBC analyst Trung Huynh said early-stage comparisons are “immaterial,” but cautioned that Foundayo’s uptake could be viewed negatively. J.P. Morgan’s Chris Schott highlighted Wegovy’s brand recognition and longer market presence as reasons for its stronger early performance.
Investor Concerns and Analyst Skepticism
The slower ramp triggered a sell-off, with Lilly’s stock down nearly 5 % in Friday trading. Critics argue that without robust sampling programs and broader telehealth capture, Foundayo may struggle to close the gap with Novo’s established oral product. The share decline coincided with investor concerns about the drug’s market traction.
Conflicting Reports & Data Gaps
All sources agree on the prescription counts, but Lilly’s disclaimer notes that IQVIA data may omit prescriptions from certain pharmacy networks, creating uncertainty about the true market penetration picture.
Verbatim Quotes
> “While we believe comparisons early into launch should be considered immaterial, Foundayo’s uptake this week is likely to be received negatively,” — Trung Huynh, RBC Capital Markets analyst
Why It Matters and What’s Next
Oral obesity therapies are seen as the next growth frontier in metabolic disease treatment. Foundayo’s market performance will shape Lilly’s ability to diversify beyond its injectable Zepbound and to challenge Novo’s dominance in the semaglutide space. Analysts expect trends to clarify after two to three months, and reaching the 300,000-prescription target by year-end remains critical for the $1.3-$1.5 billion sales outlook.
